For Novo Nordisk, the first week of June represents a rare collision of forces: a high-stakes readout from its most important pipeline candidate and the imminent opening of a vast new US reimbursement channel. The Danish drugmaker is heading into the American Diabetes Association’s Scientific Sessions in New Orleans with 40 abstracts, yet the market’s attention zeroes in on exactly two — the Phase 3 REIMAGINE results for CagriSema and the Phase 2b data for Zenagamtid.
Shares closed Wednesday at €36.40, a level that underscores how much ground has been lost. The stock has fallen 18.54% since the start of the year and 42.64% over the past twelve months, sitting well below the 52-week peak of €70.13. Analysts have grown cautious, with Goldman Sachs reiterating a Hold rating this week. The consensus target from 23 Wall Street houses stands at $65.56, though the range is an unusually wide $40 to $175 — a reflection of the deep disagreement over pipeline potential versus competitive and pricing risks.
The REIMAGINE data, being presented from 5 June, will offer the first broad public look at CagriSema’s efficacy in type 2 diabetes. The weekly injection combines the amylin analogue cagrilintid with semaglutide, and Novo filed it with the FDA in December 2025. A decision is due in the fourth quarter of 2026, with a US launch pencilled in for early 2027. The stakes are high: convincing data could shift the narrative back toward pipeline strength, while any ambiguity would amplify doubts about the company’s ability to succeed Eli Lilly in the GLP-1 wars.
Zenagamtid, previously known as Amycretin, targets both GLP-1 and amylin receptors in a once-weekly injectable format. The Phase 2b readout is meant to demonstrate that Novo Nordisk can develop next-generation metabolic therapies beyond the current semaglutide franchise. The company will also present new data on Ozempic and Wegovy, widening the evidence base for semaglutide in cardiometabolic disease.
Commercially, the company has some tailwinds. Injectable Wegovy revenue rose 12% in the first quarter of 2026, and prescriptions of the oral Wegovy pill have exceeded 2 million since its US launch earlier this year. In Europe, the CHMP issued a positive opinion in May for oral semaglutide 25 mg as a weight management treatment, and a formal EU approval would make Wegovy the first GLP-1 tablet for obesity on the continent. Novo also plans to introduce a 7.2 mg Wegovy single-dose pen in the EU in the third quarter of 2026.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Yet the most disruptive news comes from the reimbursement side. Starting 1 July, eligible Medicare beneficiaries with obesity will gain access to Wegovy (both injectable and oral) for a monthly copay of $50. That represents a major policy shift: Medicare had long been prohibited from covering prescription drugs specifically for weight loss. Novo Nordisk and Eli Lilly have agreed to a net price of $245 per month — far below list prices of over $1,000. The program runs through 31 December 2027 and could bring millions of new patients into the treatment pool, but at the cost of significantly lower realised revenue per patient.
That pricing pressure is already baked into Novo Nordisk’s 2026 outlook, which calls for a 5% to 13% decline in both sales and operating profit. The guidance factors in lower US net prices, reduced Medicaid rebates for obesity therapies, and the impact of a most-favoured-nation pricing arrangement. On top of that, semaglutide’s exclusivity is eroding in some international markets, making the pipeline readouts even more urgent.
The company continues to defend its stock through buybacks. The 15 billion DKK programme, launched on 4 February, has so far repurchased 17.89 million B-shares at an average price of 263.47 DKK, for a total outlay of 4.71 billion DKK. Novo holds 35.07 million B-shares in treasury, equivalent to 0.8% of share capital. The current tranche is expected to run until early February 2027.
All these threads come together on 7 June, when Novo Nordisk hosts its R&D investor day at 18:30 CDT. The live webcast is meant to contextualise the conference data and lay out a clear regulatory pathway for CagriSema. The market will be listening for two things: how robust the REIMAGINE results are, and how confidently management projects the path to a fourth-quarter FDA decision. Strong clinical data combined with a credible commercial roadmap could give the stock a much-needed counterweight to the pricing headwinds. Weak or equivocal results, on the other hand, would leave the new Medicare volume as a consolation prize — one that comes with razor-thin margins.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from June 4 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 4.
Novo Nordisk: Buy or sell? Read more here...
